Results 1 to 10 of about 1,365,991 (387)

Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: Results from STEM trial [PDF]

open access: yes, 2007
Purpose: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women. We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the ...
Dowsett, Mitch   +10 more
core   +2 more sources

‘Placebos’ and the logic of placebo comparison [PDF]

open access: yesBiology & Philosophy, 2011
Robin Nunn has argued that we should stop using the terms ‘placebo’ and ‘placebo effect’. I argue in support of Nunn’s position by considering the logic of why we perform placebo comparisons. Like all comparisons, placebo comparison is just a case of comparing one thing with another, but it is a mistake, I argue, to think of placebo comparison as a ...
openaire   +4 more sources

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

open access: yesNew England Journal of Medicine, 2016
BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.
F. Nevens   +31 more
semanticscholar   +1 more source

Regulation with Placebo Effects [PDF]

open access: yes, 2008
A growing scientific literature supports the existence of placebo effects from a wide range of health interventions and for a range of medical conditions.
Malani, Anup
core   +1 more source

Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial [PDF]

open access: yes, 2012
BACKGROUND Depression is a common and costly comorbidity in dementia. There are very few data on the cost-effectiveness of antidepressants for depression in dementia and their effects on carer outcomes. AIMS To evaluate the cost-effectiveness of
Alan Thomas   +29 more
core   +1 more source

Placebo Effect [PDF]

open access: yesThe Scientific World Journal, 2000
Nature and Science ran completely different news line-ups this week. But their lead stories agreed on one thing: patients matter. Nature led with a story about a group of patients who will share in a patent after giving blood and tissue samples to scientists.
openaire   +3 more sources

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis [PDF]

open access: yesJournal of Vector Borne Diseases, 2008
Background & objectives: Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment ...
M.A. Nilforoushzadeh   +5 more
doaj  

Six months follow up of a single intravitreal injection of ocriplasmin for symptomatic vitreomacular adhesion [PDF]

open access: yes, 2016
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125 μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up.
GUZZO, Anna Santa   +6 more
core   +2 more sources

Placebo by proxy

open access: yesBMJ, 2011
Clinicians’ and family members’ feelings and perceptions about a treatment may influence their judgments about its ...
David J. Grelotti, Ted J. Kaptchuk
openaire   +4 more sources

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2016
IMPORTANCE Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.
P. Miller   +12 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy